| Literature DB >> 27843752 |
Nonita Dhirar1, Jyoti Khandekar1, Damodar Bachani1, Deonath Mahto2.
Abstract
BACKGROUND: Thalassemia Major is a preventable genetic disorder characterized by abnormal hemoglobin synthesis and lifelong blood transfusions. The children suffering from Thalassemia Major have poor quality of life. This study was conducted to assess the factors influencing quality of life of these children and how it can be improved.Entities:
Keywords: Beta Thalassemia Major; Hemoglobinopathies; Quality of life
Year: 2016 PMID: 27843752 PMCID: PMC5084148 DOI: 10.1186/s40064-016-3568-4
Source DB: PubMed Journal: Springerplus ISSN: 2193-1801
Socio-demographic and clinical characteristics of 241 children suffering from Thalassemia
| Socio-demographic and clinical characteristics | n = 241 |
|---|---|
| Mean age (years) | 8.69 ± 4.98 |
| Sex | |
| Male | 153 (63.5%) |
| Female | 88 (36.5%) |
| Religion | |
| Hindu | 172 (71.4%) |
| Muslim | 60 (24.9%) |
| Othersa | 9 (3.7%) |
| Socioeconomic status | |
| Upper | 0 (0%) |
| Middle | 122 (53%) |
| Lower | 103 (44.8%) |
| Not applicable (rural) | 5 (2.2%) |
| Type of family | |
| Joint | 107 (46.5%) |
| Nuclear | 123 (53.5%) |
| Consanguinity | |
| Yes | 47 (19.6%) |
| No | 194 (80.4%) |
| Family history of Thalassemia | |
| Yes | 69 (28.6%) |
| No | 172 (71.4%) |
| Age at onset (months) | |
| 0–6 | 165 (68.5%) |
| 7–12 | 40 (16.6%) |
| 13–18 | 14 (5.8%) |
| 19–24 | 14 (5.8%) |
| >24 | 8 (3.3%) |
| Presence of co-morbidities/complications | |
| Yes | 17 (7.1%) |
| No | 224 (92.9%) |
| Iron chelation therapy | |
| Yes | 220 (91/3%) |
| No | 21 (8.7%) |
aOthers included Sikh and Christian
Health-related quality of life (HRQoL) of the children with Beta-Thalassemia major
| Total (n = 241) | Boys (n = 153) | Girls (n = 88) | p value* | |
|---|---|---|---|---|
| Physical QoL score | 81.3 ± 21.3 | 82.3 ± 18.7 | 79.5 ± 25.1 | 0.121 |
| Psychosocial QoL score | 82.5 ± 13.1 | 83.7 ± 11.8 | 80.5 ± 14.8 | 0.079 |
| Emotional domain | 75.4 ± 17.4 | 77.7 ± 15.9 | 71.5 ± 19.1 | 0.025 |
| Social domain | 92.0 ± 17.4 | 92.8 ± 15.9 | 90.6 ± 19.7 | 0.335 |
| School functioning | 77.8 ± 14.5 | 77.5 ± 15.6 | 78.2 ± 12.7 | 0.930 |
| Total QoL score | 82.0 ± 14.4 | 83.1 ± 12.5 | 80.1 ± 17.2 | 0.131 |
Values are expressed as mean (standard deviation; SD), Statistical methods used: Mann–Whitney U test; * p < 0.05 was considered statistically significant
Univariate analysis on covariates associated with HRQoL scores among children with Beta-Thalassemia Major
| Physical QoL Score | p value | Correlation (r, p) | Psychosocial QoL score | p value | Correlation (r, p) | Total QoL score | p value | Correlation (r, p) | |
|---|---|---|---|---|---|---|---|---|---|
| Age | |||||||||
| 2–4 years (n = 68) | 88.9 ± 21.6 | 0.001 | (−0.243, 0.000) | 86.1 ± 12.6 | 0.000 | (−0.229, 0.000) | 87.4 ± 14.2 | 0.000 | (−0286, 0.000) |
| 5–7 years (n = 43) | 83.2 ± 16.4 | 85.5 ± 10.7 | 84.5 ± 10.7 | ||||||
| 8–12 years (n = 61) | 75.7 ± 23.5 | 77.7 ± 14.3 | 76.7 ± 15.6 | ||||||
| 13–18 years (n = 69) | 77.5 ± 19.4 | 81.5 ± 12.4 | 79.9 ± 13.6 | ||||||
| Comorbidity | |||||||||
| Yes (n = 17) | 67.0 ± 25.9 | 0.008 | (−0.173, 0.007) | 76.9 ± 16.6 | 0.157 | (−0.093, 0.150) | 72.8 ± 18.5 | 0.026 | (−0.145, 0.024) |
| No (n = 234) | 82.4 ± 20.5 | 82.9 ± 12.7 | 82.7 ± 13.9 | ||||||
| Type of Iron chelation therapy | |||||||||
| Only oral (n = 213) | 81.2 ± 21.3 | 0.103 | 82.0 ± 12.4 | 0.000 | 81.7 ± 13.9 | 0.003 | |||
| Only subcutaneous (n = 3) | 67.7 ± 17.8 | 78.3 ± 19.2 | 74.6 ± 17.2 | ||||||
| Oral +subcutaneous (n = 4) | 73.4 ± 14.6 | 75.4 ± 12.5 | 74.6 ± 13.0 | ||||||
| No ICT (n = 21) | 86.1 ± 21.9 | 89.7 ± 17.2 | 88.1 ± 18.6 | ||||||
| Frequency of Hospital visits/month | |||||||||
| 1 (n = 196) | 83.1 ± 20.4 | 0.012 | (−0.162, 0.009) | 82.9 ± 12.9 | 0.213 | (−0.50,0.420) | 82.9 ± 14.1 | 0.044 | (−0.127, 0.050) |
| 2 (n = 43) | 74.6 ± 23.2 | 81.3 ± 13.5 | 78.7 ± 15.4 | ||||||
| 3 (n = 2) | 51.6 ± 6.6 | 69.2 ± 1.2 | 63.0 ± 3.07 | ||||||
Values are expressed as mean (standard deviation; SD), Statistical methods used: Mann–Whitney U test for difference between groups, Correlation coefficient measured for correlation; * p < 0.05 was considered statistically significant
Multiple linear regression analysis on predictors of the HRQoL scores on subscales of Peds QoL reports
| R | R2 | F (DF, P) | β coefficient | p value* | |
|---|---|---|---|---|---|
| Physical QoL | 0.325 | 0.106 | 4.617 (6, 234) | 105.468 | 0.000 |
| Age in completed years | 0.459 | 0.647 | |||
| Age of onset in months | −1.913 | 0.057 | |||
| Number of comorbidities | −1.665 | 0.097 | |||
| Duration of treatment in years | −0.687 | 0.493 | |||
| Frequency of transfusion per month | −1.959 | 0.051 | |||
| Number of Concomitant medications | −1.510 | 0.132 | |||
| Psychosocial QoL | 0.211 | 0.044 | 3.663 (3, 237) | 88.327 | 0.013 |
| Age in completed years | −2.309 | 0.207 | |||
| Duration of treatment | 1.432 | 0.441 | |||
| Total number of visits per year | −0.101 | 0.793 | |||
| Total QoL | 0.310 | 0.096 | 3.536 (7, 233) | 97.264 | 0.001 |
| Age in completed years | −0.012 | 0.994 | |||
| Age of onset in months | −0.280 | 0.109 | |||
| Frequency of transfusion per month | −2.529 | 0.305 | |||
| Duration of treatment in years | −0.408 | 0.806 | |||
| Number of Concomitant medications | −2.193 | 0.213 | |||
| Total number of visits per year | −0.093 | 0.741 | |||
| Number of comorbidities | −4.902 | 0.094 |
Statistical method used: multiple linear regression; * p < 0.05 was considered statistically significant